Cargando…
Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016–2020
BACKGROUND: Whether the high cost of cancer drugs is commensurate with their value to patients, which has become the focus of public concern. We aimed to assess the value of new cancer drugs approved for solid cancer in China and to explore the association between price and value of drugs. METHODS:...
Autores principales: | Luo, Jing, Ou, Shunlong, Wei, Hua, Qin, Xiaoli, Peng, Rui, Wang, Song, Jiang, Qian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998930/ https://www.ncbi.nlm.nih.gov/pubmed/36908440 http://dx.doi.org/10.3389/fpubh.2023.1109668 |
Ejemplares similares
-
Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020) -
China NMPA perspective on clinical evaluation of SARS-CoV-2 antibody test reagents in the process of emergency approval
por: Lv, Yunfeng, et al.
Publicado: (2020) -
NMPA-approved traditional Chinese medicine-Pingwei Pill: new indication for colistin recovery against MCR-positive bacteria infection
por: Sheng, Qiushuang, et al.
Publicado: (2021) -
Investigation of
Temperature Cycling with Coupled
Vessels for Efficient Deracemization of NMPA
por: Rehman, Ghufran ur, et al.
Publicado: (2023) -
Spatio-Temporal Distribution and Demographic Characteristics of Congenital Heart Defects in Guangdong, China, 2016–2020
por: Miao, Huazhang, et al.
Publicado: (2022)